Anastrozole
- Generic Name
- Anastrozole
- Brand Names
- Arimidex
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N5
- CAS Number
- 120511-73-1
- Unique Ingredient Identifier
- 2Z07MYW1AZ
- Background
Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...
- Indication
Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...
- Associated Conditions
- Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
Pre-Surgical Intervention for Targeted Therapies for Breast Cancer
- First Posted Date
- 2009-10-30
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 10
- Registration Number
- NCT01004744
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)
- Conditions
- Interventions
- First Posted Date
- 2009-07-23
- Last Posted Date
- 2011-08-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 25
- Registration Number
- NCT00944918
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Arimidex Therapy Compliance Electronic Monitoring System
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2012-02-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 104
- Registration Number
- NCT00936442
- Locations
- 🇧🇪
Research Site, Overpelt, Belgium
Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2009-05-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 540
- Registration Number
- NCT00902954
- Locations
- 🇨🇳
Jinsong Lu, Shanghai, Shanghai, China
Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-05-05
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Centre Oscar Lambret
- Target Recruit Count
- 44
- Registration Number
- NCT00893061
- Locations
- 🇫🇷
Centre Paul Strauss, Strasbourg, France
🇫🇷Centre Eugene Marquis, Rennes, France
🇫🇷Centre Oscar Lambret, Lille, France
Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Institut Bergonié
- Target Recruit Count
- 120
- Registration Number
- NCT00871858
- Locations
- 🇫🇷
Institut Bergonie, Bordeaux, France
ATAC - Pharmacokinetics (PK) Sub-Protocol
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2009-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 9358
- Registration Number
- NCT00784862
ATAC - Quality of Life Sub-Protocol
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2009-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 308
- Registration Number
- NCT00784680
ATAC - Bone Density Sub-Protocol
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2009-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 308
- Registration Number
- NCT00784940
Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 250
- Registration Number
- NCT00738777
- Locations
- 🇳🇱
UMC St. Radboud, Nijmegen, Netherlands
🇳🇱NKI-AVL, Amsterdam, Netherlands
🇳🇱Medisch Centrum Haaglanden, den Haag, ZH, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.